

## AFFIDAVIT OF NATHANIEL E FRANK-WHITE

1. I am a Records Request Processor at the Internet Archive. I make this declaration of my own personal knowledge.
2. The Internet Archive is a website that provides access to a digital library of Internet sites and other cultural artifacts in digital form. Like a paper library, we provide free access to researchers, historians, scholars, and the general public. The Internet Archive has partnered with and receives support from various institutions, including the Library of Congress.
3. The Internet Archive has created a service known as the Wayback Machine. The Wayback Machine makes it possible to browse more than 450 billion pages stored in the Internet Archive's web archive. Visitors to the Wayback Machine can search archives by URL (i.e., a website address). If archived records for a URL are available, the visitor will be presented with a display of available dates. The visitor may select one of those dates, and begin browsing an archived version of the Web. Links on archived files in the Wayback Machine point to other archived files (whether HTML pages or other file types), if any are found for the URL indicated by a given link. For instance, the Wayback Machine is designed such that when a visitor clicks on a hyperlink on an archived page that points to another URL, the visitor will be served the archived file found for the hyperlink's URL with the closest available date to the initial file containing the hyperlink.
4. The archived data made viewable and browsable by the Wayback Machine is obtained by use of web archiving software that automatically stores copies of files available via the Internet, each file preserved as it existed at a particular point in time.
5. The Internet Archive assigns a URL on its site to the archived files in the format `http://web.archive.org/web/[Year in yyyy][Month in mm][Day in dd][Time code in hh:mm:ss]/[Archived URL]` aka an "extended URL". Thus, the extended URL `http://web.archive.org/web/19970126045828/http://www.archive.org/` would be the URL for the record of the Internet Archive home page HTML file (`http://www.archive.org/`) archived on January 26, 1997 at 4:58 a.m. and 28 seconds (1997/01/26 at 04:58:28). The date indicated by an extended URL applies to a preserved instance of a file for a given URL, but not necessarily to any other files linked therein. Thus, in the case of a page constituted by a primary HTML file and other separate files (e.g., files with images, audio, multimedia, design elements, or other embedded content) linked within that primary HTML file, the primary HTML file and the other files will each have their own respective extended URLs and may not have been archived on the same dates.
6. Attached hereto as Exhibit A are true and accurate copies of browser screenshots of the Internet Archive's records of the archived files for the URLs and the dates specified in the attached coversheet of each printout.

DEXCOM EXHIBIT 1052  
*Dexcom v. Abbott*  
IPR2023-01251





7. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

DATE: 08/16/2024

Nathaniel Frank-White  
Nathaniel E Frank-White

Please see attached  
All Purpose  
Jurat form  
for additional  
Notary Events



## JURAT ATTACHMENT


A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

STATE OF Texas }

COUNTY OF Harris }

The foregoing instrument was subscribed and sworn before me this date of 08/16/2024, by Nathaniel Frank-White

This notarial act was an online notarization.



Notary's Signature Ana Laura Salazar Uribe

Registration No.: 131757026

Commission Expiration Date: October 11, 2026



# EXHIBIT A

<https://web.archive.org/web/20071025085348/http://www.medtronicdiabetes.com/professionals/realtime/clinical.html>



**Medtronic**

Alleviating Pain · Restoring Health · Extending Life

Store

CareLink

Pump School Online

Local Events

Contact Us

Home

Insulin Pump Therapy

Product Information

Help & Support

Healthcare Professionals

About Us

Why Medtronic?

MiniMed Paradigm®  
REAL-Time System

Features and Benefits

► Clinical Benefits

Professional Products

Donations and  
Consulting

Product Trainer  
Program

Pump School Online

Resource Library

How to Learn More

Request Insulin  
Pump Info

Request Guardian  
REAL-Time Info

Patient Information  
Events

Find a Physician

Important Safety  
Information

E-mail This Page

Print This Page

Home ► Healthcare Professionals ► REAL-Time System ► Clinical Benefits

## Improve Clinical Outcomes with Insulin Pump Therapy and Continuous Glucose Monitoring

Type Size + -

The revolutionary MiniMed Paradigm® REAL-Time System offers the benefits of both insulin pump therapy and continuous glucose monitoring. Insulin pump therapy is proven to improve patient outcomes versus multiple daily injections (MDI) with long-acting insulin (glargine). [1,2](#) Continuous glucose monitoring as an adjunct to fingersticks is proven to improve these outcomes versus fingersticks alone. [3-5](#)

Benefits of Insulin Pump Therapy with Continuous Glucose Monitoring:

- Works more like the systems of the human body
- Better detects hypoglycemia for more proactive patient management [6,7](#)
- Reduces HbA1c levels, which reduces the risk of serious diabetes complications [2,8](#)

### Works More Like the Human Body

- Continuous glucose monitoring measures glucose levels continuously, like the systems of the human body. Just as the body uses this information to guide insulin release, continuous glucose monitoring helps patients to guide therapy decisions
- Insulin pump therapy delivers insulin with programmable basal rates and programmable bolus dosing – day or night – to suit unique patient requirements. This is similar to the function of a healthy pancreas [9](#)


### Continuous Glucose Monitoring is an Important Supplement to Fingersticks and HbA1c Testing

- Continuous glucose monitoring works more like the human body than HbA1c testing and fingersticks because glucose levels are measured throughout the day and night
- HbA1c testing is performed at a single point in time, once every 2 to 3 months
- Fingersticks also measure glucose levels at a single point in time – patients test on average only 4 to 5 times per day

Now iCan

### See the REAL picture

Fingersticks show only part of the picture



Based on an individual taking 4 fingersticks per day, at the times shown. Continuous glucose monitoring shows highs and lows that these fingersticks may miss.

### Insulin Pump Therapy vs. MDI with Long-Acting Insulin

- Insulin pump therapy works more like a healthy pancreas than MDI with long-acting insulin because it customizes a patient's therapy to his/her unique needs
- MDI with long-acting insulin locks patients into nonadjustable insulin injections regardless of individual requirements

### Better Detects Hypoglycemia for More Proactive Patient Management

By offering the clinical benefits of both insulin pump therapy and continuous glucose monitoring, the MiniMed Paradigm® REAL-Time system enables you and your patients to achieve the following:


- Better detection of hypoglycemia and hyperglycemia vs. fingersticks alone [10-13](#)
- Reduction in hypoglycemia vs. MDI [14,15](#) and MDI with long-acting insulin (glargine) [16](#)

## Better Reveals Dangerous Glucose Variability

Continuous glucose monitoring helps reveal glucose variability not tracked by fingersticks or HbA1c testing [17](#)

- 60% of lows may not be revealed when using fingersticks alone [18,19](#)
- HbA1c testing provides a 2 to 3 month average of glucose levels and isn't intended to track highs and lows [17](#)
- Continuous glucose monitoring identifies 4 times more glucose excursions requiring therapy adjustment versus fingersticks alone [20](#)

## REAL-Time Alarms helped reduce the duration of hypoglycemic excursions




Patient response to REAL-Time Alarms resulted in a 48% reduction in mean duration of hypoglycemic excursions (from 64.4 minutes to 33.6 minutes) [21](#)

## Reduces Hypoglycemia vs. MDI with long-acting insulin (glargine)

Insulin pump therapy has been consistently associated with fewer cases of severe hypoglycemia [22,23](#)

- Insulin pump therapy patients showed a 73.8% reduction in the frequency of severe hypoglycemia vs. MDI patients [22](#)
- Insulin pump therapy patients spent only 12.8% of time overnight at BG < 70 mg/dL vs. 34.7% of time overnight spent by MDI with long-acting insulin (glargine) patients [24](#)

## REAL-Time readings allow patients to take preventative action to avoid potential highs and lows\*





\* Illustrative model only. Not based on actual patient study.

## Can Help Reduce HbA1c Levels and Complications

- Continuous glucose monitoring has been shown to help guide therapy adjustment and, therefore, reduce HbA1c levels versus the use of fingersticks alone [25-27](#)
- Insulin pump therapy helped achieve the HbA1c target of 7% or less in 50% of patients versus only 12% of patients using MDI with long-acting insulin (glargine) [28](#)

## Continuous glucose monitoring reduces HbA1c levels vs. fingersticks





### Insulin pump therapy reduces HbA1c vs. MDI with long-acting insulin (glargine) <sup>28</sup>

### Reducing HbA1c levels reduces the risk of long-term diabetes complications.

- By reducing HbA1c levels, insulin pump therapy and continuous glucose monitoring help to increase a patient's lifespan <sup>29,30</sup>
- Each 1% reduction in HbA1c reduces the risk of long-term complications like eye, nerve, kidney and heart diseases by 15% to 30% <sup>29,30</sup>

- <sup>1</sup> Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. *Diabetes Care*. 2005;28(3):533-8.
- <sup>2</sup> Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-8.
- <sup>3</sup> Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- <sup>4</sup> Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- <sup>5</sup> Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- <sup>6</sup> Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- <sup>7</sup> Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- <sup>8</sup> American Diabetes Association: Standards of Medical care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- <sup>9</sup> Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century: Strategies for successful use in adults, adolescents, and children with diabetes. *Postgraduate Medicine*. 2002;111(5):69-77.
- <sup>10</sup> Derr R, Garrett E, Stacy G, et al. Is HbA1c affected by glycemic instability? *Diabetes Care*. 2003;26(10): 2728-33.
- <sup>11</sup> Gross TM, Mastrototaro JJ. Efficacy and Reliability of the Continuous Glucose Monitoring System. *Diabetes Technol Ther*. 2000;2(Suppl 1):S19-26.
- <sup>12</sup> Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. *Diabetes Technol Ther*. 2000;2(Suppl 1):S7-12.
- <sup>13</sup> Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- <sup>14</sup> Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- <sup>15</sup> Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- <sup>16</sup> Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. *Diabetes Care*. 2003;26(4):1322.
- <sup>17</sup> Derr R, Garrett E, Stacy G, et al. Is HbA1c affected by glycemic instability? *Diabetes Care*. 2003;26(10): 2728-33.
- <sup>18</sup> Gross TM, Mastrototaro JJ. Efficacy and Reliability of the Continuous Glucose Monitoring System. *Diabetes Technol Ther*. 2000;2(Suppl 1):S19-26.
- <sup>19</sup> Skyler JS. The economic burden of diabetes and the benefits of improved

- 20 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 21 Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous glucose monitoring system. *Diabetes Technol Ther*. 2004;6(2):105-13.
- 22 Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- 23 Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- 24 Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. *Diabetes Care*. 2003;26(4):1322.
- 25 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 26 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 27 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- 28 Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-1558.
- 29 American Diabetes Association: Standards of Medical care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- 30 Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;277(5):374-5.





**Medtronic**

Alleviating Pain · Restoring Health · Extending Life

Store

CareLink

Pump School Online

Local Events

Contact Us

Home

Insulin Pump Therapy

Product Information

Help & Support

Healthcare Professionals

About Us

Why Medtronic?

MiniMed Paradigm®  
REAL-Time System

Features and Benefits

► Clinical Benefits

Professional Products

Donations and  
Consulting

Product Trainer  
Program

Pump School Online

Resource Library



How to Learn More



Request Insulin  
Pump Info



Request Guardian  
REAL-Time Info



Patient Information  
Events



Find a Physician

Important Safety  
Information

E-mail This Page

Print This Page

Home ► Healthcare Professionals ► REAL-Time System ► Clinical Benefits

## Improve Clinical Outcomes with Insulin Pump Therapy and Continuous Glucose Monitoring

Type Size + -

The revolutionary MiniMed Paradigm® REAL-Time System offers the benefits of both insulin pump therapy and continuous glucose monitoring. Insulin pump therapy is proven to improve patient outcomes versus multiple daily injections (MDI) with long-acting insulin (glargine). [1,2](#) Continuous glucose monitoring as an adjunct to fingersticks is proven to improve these outcomes versus fingersticks alone. [3-5](#)

Benefits of Insulin Pump Therapy with Continuous Glucose Monitoring:

- Works more like the systems of the human body
- Better detects hypoglycemia for more proactive patient management [6,7](#)
- Reduces HbA1c levels, which reduces the risk of serious diabetes complications [2,8](#)

### Works More Like the Human Body

- Continuous glucose monitoring measures glucose levels continuously, like the systems of the human body. Just as the body uses this information to guide insulin release, continuous glucose monitoring helps patients to guide therapy decisions
- Insulin pump therapy delivers insulin with programmable basal rates and programmable bolus dosing – day or night – to suit unique patient requirements. This is similar to the function of a healthy pancreas [9](#)


### Continuous Glucose Monitoring is an Important Supplement to Fingersticks and HbA1c Testing

- Continuous glucose monitoring works more like the human body than HbA1c testing and fingersticks because glucose levels are measured throughout the day and night
- HbA1c testing is performed at a single point in time, once every 2 to 3 months
- Fingersticks also measure glucose levels at a single point in time – patients test on average only 4 to 5 times per day

Now iCan

### See the REAL picture

Fingersticks show only part of the picture



Based on an individual taking 4 fingersticks per day, at the times shown. Continuous glucose monitoring shows highs and lows that these fingersticks may miss.

### Insulin Pump Therapy vs. MDI with Long-Acting Insulin

- Insulin pump therapy works more like a healthy pancreas than MDI with long-acting insulin because it customizes a patient's therapy to his/her unique needs
- MDI with long-acting insulin locks patients into nonadjustable insulin injections regardless of individual requirements

### Better Detects Hypoglycemia for More Proactive Patient Management

By offering the clinical benefits of both insulin pump therapy and continuous glucose monitoring, the MiniMed Paradigm® REAL-Time system enables you and your patients to achieve the following:


- Better detection of hypoglycemia and hyperglycemia vs. fingersticks alone [10-13](#)
- Reduction in hypoglycemia vs. MDI [14,15](#) and MDI with long-acting insulin (glargine) [16](#)

## Better Reveals Dangerous Glucose Variability

Continuous glucose monitoring helps reveal glucose variability not tracked by fingersticks or HbA1c testing [17](#)

- 60% of lows may not be revealed when using fingersticks alone [18,19](#)
- HbA1c testing provides a 2 to 3 month average of glucose levels and isn't intended to track highs and lows [17](#)
- Continuous glucose monitoring identifies 4 times more glucose excursions requiring therapy adjustment versus fingersticks alone [20](#)

## REAL-Time Alarms helped reduce the duration of hypoglycemic excursions [21](#)




Patient response to REAL-Time Alarms resulted in a 48% reduction in mean duration of hypoglycemic excursions (from 64.4 minutes to 33.6 minutes) [21](#)

## Reduces Hypoglycemia vs. MDI with long-acting insulin (glargine)

Insulin pump therapy has been consistently associated with fewer cases of severe hypoglycemia [22,23](#)

- Insulin pump therapy patients showed a 73.8% reduction in the frequency of severe hypoglycemia vs. MDI patients [22](#)
- Insulin pump therapy patients spent only 12.8% of time overnight at BG < 70 mg/dL vs. 34.7% of time overnight spent by MDI with long-acting insulin (glargine) patients [24](#)

## REAL-Time readings allow patients to take preventative action to avoid potential highs and lows\*





\* Illustrative model only. Not based on actual patient study.

## Can Help Reduce HbA1c Levels and Complications

- Continuous glucose monitoring has been shown to help guide therapy adjustment and, therefore, reduce HbA1c levels versus the use of fingersticks alone [25-27](#)
- Insulin pump therapy helped achieve the HbA1c target of 7% or less in 50% of patients versus only 12% of patients using MDI with long-acting insulin (glargine) [28](#)

## Continuous glucose monitoring reduces HbA1c levels vs. fingersticks [27](#)





### Insulin pump therapy reduces HbA1c vs. MDI with long-acting insulin (glargine) <sup>28</sup>

### Reducing HbA1c levels reduces the risk of long-term diabetes complications.

- By reducing HbA1c levels, insulin pump therapy and continuous glucose monitoring help to increase a patient's lifespan <sup>29,30</sup>
- Each 1% reduction in HbA1c reduces the risk of long-term complications like eye, nerve, kidney and heart diseases by 15% to 30% <sup>29,30</sup>

- <sup>1</sup> Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. *Diabetes Care*. 2005;28(3):533-8.
- <sup>2</sup> Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-8.
- <sup>3</sup> Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- <sup>4</sup> Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- <sup>5</sup> Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- <sup>6</sup> Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- <sup>7</sup> Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- <sup>8</sup> American Diabetes Association: Standards of Medical care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- <sup>9</sup> Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century: Strategies for successful use in adults, adolescents, and children with diabetes. *Postgraduate Medicine*. 2002;111(5):69-77.
- <sup>10</sup> Derr R, Garrett E, Stacy G, et al. Is HbA1c affected by glycemic instability? *Diabetes Care*. 2003;26(10): 2728-33.
- <sup>11</sup> Gross TM, Mastrototaro JJ. Efficacy and Reliability of the Continuous Glucose Monitoring System. *Diabetes Technol Ther*. 2000;2(Suppl 1):S19-26.
- <sup>12</sup> Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. *Diabetes Technol Ther*. 2000;2(Suppl 1):S7-12.
- <sup>13</sup> Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- <sup>14</sup> Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- <sup>15</sup> Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- <sup>16</sup> Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. *Diabetes Care*. 2003;26(4):1322.
- <sup>17</sup> Derr R, Garrett E, Stacy G, et al. Is HbA1c affected by glycemic instability? *Diabetes Care*. 2003;26(10): 2728-33.
- <sup>18</sup> Gross TM, Mastrototaro JJ. Efficacy and Reliability of the Continuous Glucose Monitoring System. *Diabetes Technol Ther*. 2000;2(Suppl 1):S19-26.
- <sup>19</sup> Skyler JS. The economic burden of diabetes and the benefits of improved

- 20 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 21 Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous glucose monitoring system. *Diabetes Technol Ther*. 2004;6(2):105-13.
- 22 Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- 23 Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- 24 Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. *Diabetes Care*. 2003;26(4):1322.
- 25 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 26 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 27 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- 28 Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-1558.
- 29 American Diabetes Association: Standards of Medical care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- 30 Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;277(5):374-5.





**Medtronic**

*Alleviating Pain · Restoring Health · Extending Life*

[Store](#)

[CareLink](#)

[Pump School Online](#)

[Local Events](#)

[Contact Us](#)

[Home](#)

[Insulin Pump Therapy](#)

[Product Information](#)

[Help & Support](#)

[Healthcare Professionals](#)

[About Us](#)

**Why Medtronic?**

**MiniMed Paradigm®  
REAL-Time System**

[Features and Benefits](#)

[Clinical Benefits](#)

**Professional Products**

**Donations and  
Consulting**

**Product Trainer  
Program**

**Pump School Online**

**Resource Library**



[How to Learn More](#)



[Request Insulin  
Pump Info](#)



[Request Guardian  
REAL-Time Info](#)



[Patient Information  
Events](#)



[Find a Physician](#)



[Important Safety  
Information](#)



[E-mail This Page](#)



[Print This Page](#)

[Home](#) [Healthcare Professionals](#) [REAL-Time System](#) [Features and Benefits](#)

## The MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System

Type Size + -

For the first time, REAL-Time continuous glucose monitoring is integrated with insulin pump therapy, for insulin management that works more like the systems of the human body. The introduction of the MiniMed Paradigm® REAL-Time system represents a major step forward in diabetes management by Medtronic Diabetes, the 20-year pioneer of insulin pump therapy and continuous glucose monitoring.

### REAL-Time System Components Help Your Patients Better Manage Their Diabetes

System components include:

- Glucose sensor
- Radio frequency (RF) transmitter
- MiniMed Paradigm 522 or 722 Insulin pump
- MiniMed Paradigm infusion sets
- Solutions® Software for Pumps and Meters and CareLink™ Personal Software

#### Continuous Glucose Sensor Provides REAL Insights

- A small sensor inserts easily under the skin in a virtually painless process
- Measures current glucose levels in interstitial fluid, as an adjunct to fingerstick measurements (fingersticks are required prior to adjusting insulin delivery and when calibrating the glucose sensor)
- Accuracy is proven in numerous published studies [1-3](#)
- Patients can shower, bathe or swim while wearing the sensor and transmitter
- Glucose sensor can be used for up to 3 days

#### Radiofrequency (RF) Transmitter Allows REAL Flexibility

- Enables system components to communicate wirelessly for optimal flexibility
- Permits an active lifestyle: it is small, discreet and waterproof so your patient can wear it anytime, anywhere

#### MiniMed Paradigm 522 or 722 Insulin Pump Offers REAL Innovations

- On-screen REAL-Time glucose readings, trend arrows, and trend graphs to help patients understand more about their glucose control and improve their diabetes management
- Easy-to-use menu navigation
- Millions of safety checks for safe, reliable use
- Access to patient histories and retrospective continuous glucose trend analyses, downloaded from your patient's insulin pump to your computer. These insights can help you fine-tune basal rates and other settings more easily to optimize patient therapy more efficiently [4-6](#)

#### MiniMed Paradigm Infusion Sets Offer REAL Reliability



- Provide the security of reliable insulin administration around the clock
- Accommodate the unique needs of every patient, with a variety of customized infusion sets to choose from
- Include automatic insertion devices, for virtually painless and reliable insertion

#### REAL Patient Histories with Retrospective Trend Graphs Improve Your Ability to Optimize Therapy

The MiniMed Paradigm REAL-Time System includes special software that downloads insulin, carbohydrate, and glucose data directly from the insulin pump to provide more meaningful insights into patient progress than a logbook alone. Now you and your patients can discover and assess a wide range of glucose trends, like previously undetected overnight lows, to help optimize patient therapy more quickly and reduce the need for patient office visits.

- Solutions Software for Pumps and Meters

- Helps you organize patient insulin, carbohydrate, and glucose data into charts, graphs and tables
- Provides comprehensive trend analyses and customizable treatment reports
- CareLink Personal software
  - Web-based system lets patients monitor their own treatment information with easy-to-follow charts, graphs and tables
  - Patients will have a better understanding of their glucose trends, like post-prandial highs, so they can be more insightful about their treatment during in-office and telephone interactions with you
  - Patients can also print out and share the reports with you during exams or e-mail them to your office

### REAL Benefits - Day and Night - for You and Your Patients

With the MiniMed Paradigm REAL-Time System, patients have access to REAL-Time glucose readings, trending and alarms around the clock so they can intervene more quickly. Also, with the special software included with the system, you and your patients can review insulin, carbohydrate and glucose data and improve awareness of glycemic patterns. This information can help you and your patients better detect and manage incidents of hypo- and hyperglycemia, which can reduce HbA1c levels [7-9](#) and related diabetes complications. [10,11](#)

### System features include:

- REAL-Time Trend Graphs
- REAL-Time Readings
- REAL-Time Trend Arrows
- REAL-Time Alarms
- REAL Patient Historical Information
- Bolus Wizard® Calculator

### REAL-Time Trend Graphs

- Viewable on-screen
- 3-hour and 24-hour glucose trending
- Show patients the effect of meals, exercise, insulin and medication on their glycemic control
- CareLink Personal software helps you and your patients to easily manage this data online so that together you can better manage their diabetes

### REAL-Time Readings

- Available every 5 minutes, 24 hours a day
- Up to 288 readings per day
- Viewable on-screen at work, during mealtime and when exercising
- Help patients increase awareness, be proactive, and improve glycemic control [12-14](#)

### REAL-Time Trend Arrows

- Point up or down to reveal the direction and degree of change of glucose trends
- Increase awareness of glucose variability
- Enable patients to address even brief fluctuations in glucose levels, which can impact the development of long-term diabetes complications like eye, nerve, kidney and heart disease [15,16](#)

### REAL-Time Alarms

- Warn patients of hyperglycemia and hypoglycemia day or night, that may not be revealed when using fingersticks alone or HbA1c testing [17](#)
- Can be preset to sound or vibrate and are easily customized to different thresholds of sensitivity
- Patient response to REAL-Time alarms results in a significant reduction in the duration of hypoglycemic excursions [17](#)


### REAL Patient Historical Information

- You and your patients can easily download information using Therapy Management Software including Solutions Software for Pumps and Meters and CareLink Personal software.
- Gain insights needed to optimize patient therapy more quickly and give patients the knowledge they need to take more responsibility for their diabetes management

### Bolus Wizard Calculator

- The MiniMed Paradigm REAL-Time System includes a patented dosing calculator that does the diabetes math for patients to help reduce math errors, improve dosage accuracy, and avoid post-prandial hypoglycemia [18](#)
- Uses a patient's personal settings, blood glucose reading, carbohydrate entry, and active insulin levels to suggest a bolus amount
- Factors in a patient's preset blood glucose target range when calculating a bolus dose to help patients "treat to target" and improve their glycemic control [18,19](#)

### The Bolus Wizard does the math for diabetes patients



|                |      |
|----------------|------|
| Food Intake:   | 45gr |
| (Meter) BG:    | 160  |
| Food:          | 3.0U |
| Correction:    | 2.0U |
| Active Ins:    | 1.0U |
| ACT to Proceed |      |
| ESC to Back Up |      |

- 1 Stell GM, Bernaba B, Saad M, et al. Accurate determination of plasma glucose during hyper- and hypoglycemia with a subcutaneous glucose sensor. *Diabetes*. 2000;49(Suppl 1):S10.
- 2 Gross TM, Mastrototaro JJ. Efficacy and Reliability of the Continuous Glucose Monitoring System. *Diabetes Technol Ther*. 2000;2(Suppl 1):S19-26.
- 3 Caplin NJ, O'Leary P, Bulsara M, et al. Subcutaneous glucose sensor values closely parallel blood glucose during insulin-induced hypoglycemia. *Diabet Med*. 2003;20:238-41.
- 4 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 5 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 6 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003 May;111(5 Pt 1):933-8.
- 7 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 8 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 9 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- 10 American Diabetes Association: Standards of Medical Care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- 11 Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;277(5):374-5.
- 12 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 13 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 14 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- 15 Derr R, Garrett E, Stacy G, et al. Is HbA1c affected by glycemic instability? *Diabetes Care*. 2003;26(10): 2728-33.
- 16 Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;277(5):374-5.
- 17 Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous glucose monitoring system. *Diabetes Technol Ther*. 2004;6(2):105-13.
- 18 Gross T, Kayne D, King A, et al. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. *Diabetes Technol Ther*. 2003;5(3):365-9.
- 19 Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. *Diabetes Care*. 1999;22(9):1501-6.





Store | CareLink | Pump School Online | Local Events | Contact Us

Home | Insulin Pump Therapy | Product Information | Help & Support | Healthcare Professionals | About Us

#### Why Medtronic?

#### MiniMed Paradigm® REAL-Time System

Features and Benefits

Clinical Benefits

#### Professional Products

Donations and Consulting

Product Trainer Program

Pump School Online

Resource Library

How to Learn More

Request Insulin Pump Info

Request Guardian REAL-Time Info

Patient Information Events

Find a Physician

Important Safety Information

E-mail This Page

Print This Page

Home > Healthcare Professionals > REAL-Time System

## REAL Treatment Optimization Around the Clock

Type Size + -

The New MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System

The World's First Integrated Insulin Pump System with REAL-Time Continuous Glucose Readings



Now for the first time, REAL-Time continuous glucose monitoring is integrated with an insulin pump. This first-in-class system gives patients REAL access to glucose patterns so they can intervene more quickly while making it easier for you, the healthcare provider, to optimize their diabetes management. [1-3](#)

The system includes a continuous glucose sensor, a radio frequency transmitter, and the MiniMed Paradigm 522 or 722 insulin pump. It gives patients REAL-Time glucose readings, trending, and alarms around the clock, and also includes special software that downloads valuable data from the insulin pump and glucose sensor for more in-depth insights into patient progress than a logbook alone. You and your patients will have the information you need to better detect and manage glycemic excursions to reduce HbA1c levels [1-3](#) and related diabetes complications. [4,5](#)

### Useful for Type 1 and Type 2 Patients

The components of the MiniMed Paradigm REAL-Time System can help all of your insulin-dependent patients.

Insulin pump therapy is especially helpful in cases like these:


- Nocturnal and postprandial hypoglycemia [6,7](#)
- Dawn phenomenon [8-10](#)
- Gastroparesis
- Pregnancy [11](#)
- Pediatric patients as young as 1 year old [12](#)
- LADA (latent autoimmune diabetes in adults) patients misdiagnosed as Type 2 [13](#)

### REAL Improvement for Type 1 Diabetes Patients

- Reduces HbA1c levels: Insulin pump therapy helped achieve the HbA1c target of 7% or less in 50% of patients versus only 12% of patients using MDI with long-acting insulin (glargine) [14](#)
- Reduces complication risks: Each 1% reduction in HbA1c reduces the risk of long-term complications like eye, nerve, kidney and heart disease by 15% to 30% [15](#)

### Insulin pump therapy reduces HbA1c levels vs. MDI with long-acting insulin (glargine) [14](#)






### REAL Improvement for Type 2 Patients

- Preferred by patients: Type 2 diabetes patients preferred an insulin pump to injections when initiating insulin therapy [16](#)
- Improves satisfaction and adherence: Overall, Type 2 diabetes patients using insulin pump therapy are happier with the treatment than those on injections, which leads to better adherence [16](#)

### REAL Reduction in Hypoglycemia

- Reduces severe lows: Insulin pump therapy is consistently associated with fewer cases of severe hypoglycemia [17,18](#)
- Insulin pump therapy patients showed a 73.8% reduction in the frequency of severe hypoglycemia vs. MDI patients [17](#)
- Reduces overnight lows: Insulin pump therapy patients spent only 12.8% of time overnight at BG < 70 mg/dL vs. 34.7% of time overnight spent by MDI with long-acting insulin (glargine) patients [19](#)

### Insulin pump therapy reduces the risk of severe lows vs. MDI [17](#)



### REAL Reduction in Morning Hyperglycemia

- Affects 89% of patients: Dawn phenomenon is a morning rise in glucose levels affecting up to 89% of Type 1 diabetes patients [20](#)
- Stabilizes morning glucose levels: The variable basal rate associated with an insulin pump helps to improve morning glucose stability [21,22](#)
- Works better than long-acting insulin: The fixed basal rate associated with long-acting insulin is not flexible enough to properly manage a morning glucose rise

### REAL Management of Gastroparesis

- Adjusts to slower digestion: The MiniMed Paradigm 522 or 722 insulin pump offers exclusive programming options that daily injections cannot. Additionally, the faster-acting insulin used in insulin pump therapy has more predictable insulin action [23](#) versus long-acting insulin (glargine) [24](#)
- This more predictable absorption rate helps gastroparesis patients to better match insulin delivery to their body's slower digestion [25,26](#)
- Insulin pump therapy helps better manage hypoglycemia caused by post-injection rise in insulin levels, as well as hyperglycemia occurring during digestion once insulin levels have declined [25,26](#)

### REAL Improvement for Pregnant Patients

- Better matches fluctuating insulin requirements: Insulin pump therapy addresses the fluctuations occurring during pregnancy [27](#) better than MDI, due to programmability and more predictable insulin action [28](#)
- Reduces HbA1c levels in pregnant Type 1 patients: Post partum HbA1c levels averaged 7.2% in insulin pump users vs. 9.1% in those using MDI [29](#)
- Reduces the risk of severe adverse outcomes: Higher HbA1c levels before and during pregnancy, among other factors, are associated with severe adverse outcomes [30](#)

### REAL Benefits for LADA Patients

"Type 1.5" LADA (latent autoimmune diabetes in adults) patients have characteristics similar to Type 1 diabetes patients but may be misdiagnosed as Type 2. [31](#)

- Improves clinical outcomes: Insulin pump therapy has proven beneficial for Type 1 diabetes patients, and a diagnosis of Type 1 may be more appropriate for LADA patients than a Type 2 diagnosis
- Earlier diagnosis can drive them to intensive management including insulin pump therapy
- Insulin pump therapy reduces hypoglycemia and HbA1c levels in Type 1 diabetes patients vs. MDI [32,33](#)

- 1 Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. *Diabetes Research and Clin Practice*. 1999;46:183-90.
- 2 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 2001;24(12):2030.
- 3 Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. *Pediatrics*. 2003;111(5 Pt 1):933-8.
- 4 American Diabetes Association: Standards of Medical Care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- 5 Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;277(5):374-5.
- 6 Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- 7 Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- 8 Koivisto VA, Yki-Jarvinen H, Helve E, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. *Diabetes*. 1986;35(1):78-82.
- 9 Carroll MF, Schade DS. The dawn phenomenon revisited: Implications for diabetes therapy. *Endocr Pract*. 2005;11(1):55-64.
- 10 Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. *Diabetologia*. 1991;34(1):21-8.
- 11 Gabbe SG, Holing E, Temple P, et al. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. *Am J Obstet Gynecol*. 2000;182(6):1283-91.
- 12 Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. *Pediatrics*. 2004;114(6):1601-5.
- 13 Schernthaner G, Hink S, Kopp HP, et al. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). *Exp Clin Endocrinol Diabetes*. 2001;109 Suppl 2:S94-108.
- 14 Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-8.
- 15 American Diabetes Association: Standards of Medical Care for Patients with Diabetes Mellitus. *Diabetes Care*. 2002;25(1):S33-49.
- 16 Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized parallel-group, 24-week study. *Diabetes Care*. 2003;26(9):2598-603.
- 17 Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.
- 18 Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-7.
- 19 Armstrong D, King AB. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. *Diabetes Care*. 2003;26(4):1322.
- 20 Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. *Diabetologia*. 1991;34(1):21-8.
- 21 Koivisto VA, Yki-Jarvinen H, Helve E, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. *Diabetes*. 1986;35(1):78-82.
- 22 Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. *Endocr Pract*. 2005;11:55-64.
- 23 Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. *Diabetologia*. 1983;24(5):326-9.
- 24 Scholtz HE, van Niekerk N, Mayer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 (glargine-Lantus) compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Abstract 0882. Poster Event D: 1999, Brussels, Belgium.
- 25 Cucchiara S, Franzese A, Salvia G, et al. Gastric emptying delay and gastric electrical derangement in IDDM. *Diabetes Care*. 1998;21(3):438-43.
- 26 Tanenberg RJ, Pfeifer MA. Continuous glucose monitoring system: a new approach to the diagnosis of diabetic gastroparesis. *Diabetes Technol Ther*. 2000;2(Suppl 1):S73-80.
- 27 ADA Clinical Education Series: Medical Management of Pregnancy Complicated by Diabetes. 2000;91-3.
- 28 Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. *Diabetologia*. 1983;24(5):326-9.
- 29 Gabbe SG, Holing E, Temple P, et al. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. *Am J Obstet Gynecol*. 2000;182(6):1283-91.

by type 1 diabetes mellitus. *Am J Obstet Gynecol*. 2000;182(4):1200-21.

- 30 Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. *Diabetes Care*. 2004;27(12):2819-23.
- 31 Scherthaner G, Hink S, Kopp HP, et al. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). *Exp Clin Endocrinol Diabetes*. 2001;109 Suppl 2:S94-108.
- 32 Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care*. 2004;27:1554-8.
- 33 Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. *Endocr Pract*. 2002;8:401-5.





**Medtronic**

Alleviating Pain · Restoring Health · Extending Life

Store | CareLink | Pump School Online | Local Events | Contact Us

Home | Insulin Pump Therapy | Product Information | Help & Support | Healthcare Professionals | About Us

Why Medtronic?

MiniMed Paradigm®  
REAL-Time System

Professional Products

Donations and  
Consulting

Product Trainer  
Program

Pump School Online

Resource Library



How to Learn More



Request Insulin  
Pump Info



Request Guardian  
REAL-Time Info



Patient Information  
Events



Find a Physician



Important Safety  
Information



E-mail This Page



Print This Page



[Home](#) > [Healthcare Professionals](#)

## Healthcare Professionals

Type Size + -

### Important News!

#### Study shows improved glucose control in Type1 patients using REAL-Time continuous glucose monitoring

Data from the GuardControl Trial was published in the December 2006 issue of *Diabetes Care*. The study demonstrated that patients using Medtronic REAL-Time continuous glucose monitoring had better control of their glucose than patients using fingersticks alone.

[Clinical Summary »](#)

[Press Release »](#)

#### Right for Today, Ready for Tomorrow

At Medtronic Diabetes, helping your patients is a life-long partnership. Your patients count on you for guiding their diabetes management and we want you to count on us. As a good partner, our job is to help you provide optimal diabetes care.

#### Medtronic Diabetes:

- Brings you the #1 prescribed insulin pump therapy
- Brings you the only FDA approved continuous glucose monitoring device for professional use
- Provides a World-Class sales training and education team - making pump starts easier than ever before
- Demonstrates long-term commitment to diabetes research with more than 10% of annual revenues in research and development - 12 times the investment in 2004 than any other pump manufacturer

When you partner with Medtronic Diabetes, you choose a partner with more than two decades of experience in diabetes and the only company poised to transform the future of diabetes management.

**We are here to help** - We recognize that getting your patients up to speed and successful with insulin pump therapy and CGMS is critical to success. That's why we offer:

- [Patient Information Events](#) help your potential candidates better understand the basics
- [Online Educational Programs](#) improve pump starts, efficacy and retention
- [Continued Education Programs](#) for those ready to take their care to the next level

Of course, we continue to maintain the very best team of trained professionals, all of whom are there to assist you in your practice, detail the latest breakthroughs and provide the best one-on-one training.





**Medtronic**

Alleviating Pain · Restoring Health · Extending Life

Store | CareLink | Pump School Online | Local Events | Contact Us

Home | Insulin Pump Therapy | Product Information | Help & Support | Healthcare Professionals | About Us

**MiniMed Paradigm® REAL-Time System**

Components

► Benefits

Paradigm® Pathway™ Program

CareLink™ Personal Software

Pediatric Model

Features

Skins

Frequently Asked Questions

Ask an Expert

User Guides

Guardian® REAL-Time

CareLink™ Therapy Management Software

Infusion Sets

CGMS® System Gold™

Other Insulin Pumps

How to Learn More

Request Insulin Pump Info

Request Guardian REAL-Time Info

Patient Information Events

Find a Physician

Important Safety Information

E-mail This Page

Print This Page

Home ► Product Information ► MiniMed Paradigm® REAL-Time System ► REAL-Time Benefits

## Benefits of the MiniMed Paradigm® REAL-Time System

Type Size + -

Insulin pump therapy gives you:

- Freedom from multiple daily injections
- Freedom to eat, sleep, and exercise when you want
- Better glucose control with less risk of going low


### REAL-Time Continuous Glucose Monitoring delivers insights you just can't get through fingersticks alone.

The MiniMed Paradigm REAL-Time System delivers the most advanced insulin pump therapy available. And with continuous glucose monitoring integrated into the system, you see the big picture of your glucose levels *Right Now* – anytime, anywhere in a way that you just can't accomplish through fingersticks alone.



### See the REAL picture

Fingersticks show only part of the picture



Based on an individual taking four fingersticks per day, at the times shown. Continuous glucose monitoring shows highs and lows that these fingersticks may miss.

### And did you know that fingersticks alone may not even reveal up to 60% of lows - lows that the MiniMed Paradigm REAL-Time System can reveal? <sup>1</sup>

Fingerstick measurements reveal a blood glucose value at a single moment - a "snapshot" - in time. An A1C test, which measures blood glucose control over a two to three month period, reveals an average glucose value. Both can miss highs and lows in your blood glucose present at various times during the day highs and lows that may lead to diabetes-related complications. <sup>2</sup>

### Intervene Proactively

The MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System displays glucose readings, offers safety alarms, and displays 3- and 24-hour trend data that help you proactively intervene to improve your glucose control, and reduce the severity and duration of low and high blood sugars. Additionally, you can analyze historical glucose patterns by uploading your glucose trend data to CareLink™ Personal software, a FREE online tool. Over time, you may gain valuable understanding of the effects of meals, exercise, and medication on your glucose levels.

REAL-Time information is ideal for people trying to cope with the challenges of controlling high and low glucose levels, including people who are:

- Prone to nighttime lows ("nocturnal hypoglycemia") <sup>3</sup>
- Prone to post-meal highs ("postprandial hyperglycemia") <sup>4</sup>
- Experiencing morning highs ("dawn phenomenon") <sup>5,6</sup>
- Pregnant, or who are planning to get pregnant <sup>2</sup>

With this information, your healthcare provider can customize your diabetes treatment and reduce your A1C levels. And *that* reduces your risk of long-term health complications. <sup>2</sup>

- <sup>1</sup> Pitzer KR, et al. *Diabetes Care*. 200;24:881-885.
- <sup>2</sup> The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;227(5):374-4 Skyler JS. *Diabetes Technol Ther*. 2000;2(Suppl 1):s7-12.
- <sup>3</sup> Bode B, et al. *Diabetes Technol Ther*. 2004;6(2):105-13.
- <sup>4</sup> Bode BW, et al. *Diabetes Research and Clin Practice*. 1999. 46:183-90.
- <sup>5</sup> Kaufman FR et al. *Diabetes Care*. 2001;24(12):2030.
- <sup>6</sup> Ludvigsson J, et al. *Pediatrics*. 2003 May;111(5 Pt 1):933-8.





**Medtronic**

Alleviating Pain · Restoring Health · Extending Life

Store | CareLink | Pump School Online | Local Events | Contact Us

Home | Insulin Pump Therapy | Product Information | Help & Support | Healthcare Professionals | About Us

**MiniMed Paradigm® REAL-Time System**

Components

► Benefits

Paradigm® Pathway™ Program

CareLink™ Personal Software

Pediatric Model

Features

Skins

Frequently Asked Questions

Ask an Expert

User Guides

Guardian® REAL-Time

CareLink™ Therapy Management Software

Infusion Sets

CGMS® System Gold™

Other Insulin Pumps



How to Learn More



Request Insulin Pump Info



Request Guardian REAL-Time Info



Patient Information Events



Find a Physician



Important Safety Information



E-mail This Page



Print This Page

Home ► Product Information ► MiniMed Paradigm® REAL-Time System ► REAL-Time Benefits

## Benefits of the MiniMed Paradigm® REAL-Time System

Type Size + -

Insulin pump therapy gives you:

- Freedom from multiple daily injections
- Freedom to eat, sleep, and exercise when you want
- Better glucose control with less risk of going low


### REAL-Time Continuous Glucose Monitoring delivers insights you just can't get through fingersticks alone.

The MiniMed Paradigm REAL-Time System delivers the most advanced insulin pump therapy available. And with continuous glucose monitoring integrated into the system, you see the big picture of your glucose levels *Right Now* – anytime, anywhere in a way that you just can't accomplish through fingersticks alone.



### See the REAL picture

Fingersticks show only part of the picture



Based on an individual taking four fingersticks per day, at the times shown. Continuous glucose monitoring shows highs and lows that these fingersticks may miss.

### And did you know that fingersticks alone may not even reveal up to 60% of lows - lows that the MiniMed Paradigm REAL-Time System can reveal? <sup>1</sup>

Fingerstick measurements reveal a blood glucose value at a single moment - a "snapshot" - in time. An A1C test, which measures blood glucose control over a two to three month period, reveals an average glucose value. Both can miss highs and lows in your blood glucose present at various times during the day highs and lows that may lead to diabetes-related complications. <sup>2</sup>

### Intervene Proactively

The MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System displays glucose readings, offers safety alarms, and displays 3- and 24-hour trend data that help you proactively intervene to improve your glucose control, and reduce the severity and duration of low and high blood sugars. Additionally, you can analyze historical glucose patterns by uploading your glucose trend data to CareLink™ Personal software, a FREE online tool. Over time, you may gain valuable understanding of the effects of meals, exercise, and medication on your glucose levels.

REAL-Time information is ideal for people trying to cope with the challenges of controlling high and low glucose levels, including people who are:

- Prone to nighttime lows ("nocturnal hypoglycemia") <sup>3</sup>
- Prone to post-meal highs ("postprandial hyperglycemia") <sup>4</sup>
- Experiencing morning highs ("dawn phenomenon") <sup>5,6</sup>
- Pregnant, or who are planning to get pregnant <sup>2</sup>

With this information, your healthcare provider can customize your diabetes treatment and reduce your A1C levels. And *that* reduces your risk of long-term health complications. <sup>2</sup>

- <sup>1</sup> Pitzer KR, et al. *Diabetes Care*. 200;24:881-885.
- <sup>2</sup> The Diabetes Control and Complications Trial Research Group. *JAMA*. 1997;227(5):374-4 Skyler JS. *Diabetes Technol Ther*. 2000;2(Suppl 1):s7-12.
- <sup>3</sup> Bode B, et al. *Diabetes Technol Ther*. 2004;6(2):105-13.
- <sup>4</sup> Bode BW, et al. *Diabetes Research and Clin Practice*. 1999. 46:183-90.
- <sup>5</sup> Kaufman FR et al. *Diabetes Care*. 2001;24(12):2030.
- <sup>6</sup> Ludvigsson J, et al. *Pediatrics*. 2003 May;111(5 Pt 1):933-8.